How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making
Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of national immunisa...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136220300255 |
| _version_ | 1819059927179591680 |
|---|---|
| author | Siobhan Botwright Anna-Lea Kahn Raymond Hutubessy Patrick Lydon Joseph Biey Abdoul Karim Sidibe Ibrahima Diarra Mardiati Nadjib Auliya A. Suwantika Ery Setiawan Rachel Archer Debra Kristensen Marion Menozzi-Arnaud Ado Mpia Bwaka Jason M. Mwenda Birgitte K. Giersing |
| author_facet | Siobhan Botwright Anna-Lea Kahn Raymond Hutubessy Patrick Lydon Joseph Biey Abdoul Karim Sidibe Ibrahima Diarra Mardiati Nadjib Auliya A. Suwantika Ery Setiawan Rachel Archer Debra Kristensen Marion Menozzi-Arnaud Ado Mpia Bwaka Jason M. Mwenda Birgitte K. Giersing |
| author_sort | Siobhan Botwright |
| collection | DOAJ |
| description | Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of national immunisation programmes (NIPs) and vaccine developers. Total Systems Effectiveness (TSE) was developed as an approach to evaluate vaccines with different product attributes from a systems perspective, in order to analyse and compare the value of innovative vaccine products in different settings.The TSE approach has been advanced over the years by various stakeholders including the Bill and Melinda Gates Foundation (BMGF), Gavi, PATH, UNICEF and WHO. WHO further developed the TSE approach to incorporate the country perspective into immunisation decision-making, in order for countries to evaluate innovative products for introduction and product switch decisions, and for vaccine development stakeholders to conduct their assessments of product value in line with country preferences. This paper describes the original TSE approach, development of the tool and processes for NIPs to apply the WHO TSE approach, and results from piloting in 12 countries across Africa, Asia and the Americas. The WHO TSE framework emerged from this piloting effort.The WHO TSE approach has been welcomed by NIP and vaccine development stakeholders as a useful tool to evaluate trade-offs between different products. It was emphasised that the concept of “total systems effectiveness” is likely to be context-specific and that TSE is valuable in facilitating a deliberative process to articulate NIP priorities, for decisions around product choice, and for prioritising the development of future vaccine innovations. |
| first_indexed | 2024-12-21T14:18:52Z |
| format | Article |
| id | doaj.art-395d6bfe81e44ef3878cfda5fe201d70 |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-12-21T14:18:52Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-395d6bfe81e44ef3878cfda5fe201d702022-12-21T19:00:50ZengElsevierVaccine: X2590-13622020-12-016100078How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-makingSiobhan Botwright0Anna-Lea Kahn1Raymond Hutubessy2Patrick Lydon3Joseph Biey4Abdoul Karim Sidibe5Ibrahima Diarra6Mardiati Nadjib7Auliya A. Suwantika8Ery Setiawan9Rachel Archer10Debra Kristensen11Marion Menozzi-Arnaud12Ado Mpia Bwaka13Jason M. Mwenda14Birgitte K. Giersing15Department of Immunization, Vaccines & Biologicals, World Health Organization Headquarters, 20 Avenue Appia, 1211-CH 27 Geneva, SwitzerlandDepartment of Immunization, Vaccines & Biologicals, World Health Organization Headquarters, 20 Avenue Appia, 1211-CH 27 Geneva, SwitzerlandDepartment of Immunization, Vaccines & Biologicals, World Health Organization Headquarters, 20 Avenue Appia, 1211-CH 27 Geneva, SwitzerlandDepartment of Immunization, Vaccines & Biologicals, World Health Organization Headquarters, 20 Avenue Appia, 1211-CH 27 Geneva, SwitzerlandInter-Country Support Team, Regional Office for Africa, World Health Organization, Ouagadougou, Burkina FasoWHO Country Office for Mali (OMS/MALI), Quartier Ntomiboro-Bougou, B.P. 99, Bamako, MaliDirection Générale de la Santé et de l’Hygiène Publique, Cité Administrative Bamako, Bamako BP 232, MaliDepartment of Health Policy and Administration, Faculty of Public Health Universitas, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Indonesia Jl. Raya Bandung-Sumedang Km. 21 Jatinangor, Sumedang, West Java 45363, Indonesia; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Indonesia Jl. Raya Bandung-Sumedang Km. 21 Jatinangor, Sumedang, West Java 45363, IndonesiaDepartment of Health Policy and Administration, Faculty of Public Health Universitas, IndonesiaHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, 6th Floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Road, Muang, Nonthaburi 11000, ThailandPATH, Rue de Varembé 7, 1202 Geneva, SwitzerlandGavi, the Vaccine Alliance, Global Health Campus, Chemin du Pommier 40, 1218 Grand, Saconnex, Geneva, SwitzerlandInter-Country Support Team, Regional Office for Africa, World Health Organization, Ouagadougou, Burkina FasoRegional Office for Africa, World Health Organization, Brazzaville, CongoDepartment of Immunization, Vaccines & Biologicals, World Health Organization Headquarters, 20 Avenue Appia, 1211-CH 27 Geneva, Switzerland; Corresponding author.Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of national immunisation programmes (NIPs) and vaccine developers. Total Systems Effectiveness (TSE) was developed as an approach to evaluate vaccines with different product attributes from a systems perspective, in order to analyse and compare the value of innovative vaccine products in different settings.The TSE approach has been advanced over the years by various stakeholders including the Bill and Melinda Gates Foundation (BMGF), Gavi, PATH, UNICEF and WHO. WHO further developed the TSE approach to incorporate the country perspective into immunisation decision-making, in order for countries to evaluate innovative products for introduction and product switch decisions, and for vaccine development stakeholders to conduct their assessments of product value in line with country preferences. This paper describes the original TSE approach, development of the tool and processes for NIPs to apply the WHO TSE approach, and results from piloting in 12 countries across Africa, Asia and the Americas. The WHO TSE framework emerged from this piloting effort.The WHO TSE approach has been welcomed by NIP and vaccine development stakeholders as a useful tool to evaluate trade-offs between different products. It was emphasised that the concept of “total systems effectiveness” is likely to be context-specific and that TSE is valuable in facilitating a deliberative process to articulate NIP priorities, for decisions around product choice, and for prioritising the development of future vaccine innovations.http://www.sciencedirect.com/science/article/pii/S2590136220300255R&DVaccineDelivery technologyMCDAImmunisationPrioritisation |
| spellingShingle | Siobhan Botwright Anna-Lea Kahn Raymond Hutubessy Patrick Lydon Joseph Biey Abdoul Karim Sidibe Ibrahima Diarra Mardiati Nadjib Auliya A. Suwantika Ery Setiawan Rachel Archer Debra Kristensen Marion Menozzi-Arnaud Ado Mpia Bwaka Jason M. Mwenda Birgitte K. Giersing How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making Vaccine: X R&D Vaccine Delivery technology MCDA Immunisation Prioritisation |
| title | How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making |
| title_full | How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making |
| title_fullStr | How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making |
| title_full_unstemmed | How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making |
| title_short | How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making |
| title_sort | how can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings a total systems effectiveness tse approach to decision making |
| topic | R&D Vaccine Delivery technology MCDA Immunisation Prioritisation |
| url | http://www.sciencedirect.com/science/article/pii/S2590136220300255 |
| work_keys_str_mv | AT siobhanbotwright howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT annaleakahn howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT raymondhutubessy howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT patricklydon howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT josephbiey howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT abdoulkarimsidibe howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT ibrahimadiarra howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT mardiatinadjib howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT auliyaasuwantika howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT erysetiawan howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT rachelarcher howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT debrakristensen howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT marionmenozziarnaud howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT adompiabwaka howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT jasonmmwenda howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking AT birgittekgiersing howcanweevaluatethepotentialofinnovativevaccineproductsandtechnologiesinresourceconstrainedsettingsatotalsystemseffectivenesstseapproachtodecisionmaking |